Medical image technology represented by PET and MRI gives doctors more important information and makes modern medical treatment more precise. However, these devices are expensive and time consuming, and can only really help a part of patients. As AI technology moves to the application end, this field is undergoing revolutionary changes.
Arterial Network learned that SubtlePET, the first product of Silicon Valley's Subtle Medical, which was founded by the Chinese, has just received FDA certification. This is the first Chinese background AI medical imaging company to receive this certification and the product truly enters the US market.
Artificial intelligence innovation PET
"With SubtlePET and future products in R&D, we hope to bring low-cost, short-term, high-quality AI images and help us to help a wider patient population." Founder of Deep Medical, Stanford Electronic Engineering, Dr. Gong Enhao Said to the arterial network reporter.
As its name suggests, SubtlePET is an AI image processing platform for PET (positron emission tomography) that allows hospitals and third-party imaging centers to perform PET (including PET-CT and PET-MR) tests more quickly, serving more in one day. More patients.
PET is a commonly used imaging test in cancer treatment, neurology and cardiology. Scanning radionuclides can be used to see the functional status of patients at the molecular level. In the United States, the average price of a PET test is about $3,000 or more, which typically takes 30-60 minutes.
Deep penetration technology diagram
SubtlePET conducted early testing at Hoag Hospital, and Michael Brant-Zawadzki, MD, MD, honorary member of the American Academy of Radiology, said: "SubtlePET accelerates PET testing by up to four times and still provides the same quality medical images. The efficiency of the PET scan test also gives patients a better medical experience, while at the same time not adding any extra links or burdens to the medical process. Using SubtlePET will soon give us hospitals with economic value and competitiveness. I am looking forward to seeing more groundbreaking technologies from the deep team."
Deep technology is based on deep learning algorithms that seamlessly connect to any device manufacturer's scanning machine and PACS medical image archiving and communication system to enhance image quality during scanning without disrupting or affecting medical image acquisition. Process.
This also means that the SubtlePET product can bring a lot of quality improvement to images scanned in a short time. This feature is very important for children who can't calmly complete the test or who often need PET test.
Debut at RSNA, AI platform enhances imaging speed and reduces toner usage
Unlike other companies that perform intelligent analysis of medical images, Subtle Medical, founded by the Stanford University team, focuses on improving the imaging speed of medical devices and reducing radiation dose.
Imaging technologies such as MRI and PET are expensive and time consuming, and 90% of the cost and time consumption are actually in the process of machine imaging. The technology of deep medical treatment is cut from the machine imaging process, and the image quality is improved by AI technology. Allow medical institutions to inspect more patients and reduce radiation doses in less time.
Deep Medical has demonstrated its AI image processing platform on RSNA. After the image data comes out from the device, it directly enters the deep medical system. After processing, it enters the PACS imaging workstation for the physician to use. It is understood that Deep Medical can now accelerate the MRI and PET imaging process 4-10 times with AI technology and ensure the accuracy of the diagnostic level.
In addition to using AI to enhance imaging speed and quality, the founder of Deep Medical, Gong Enhao and his team members also published research on reducing the use of MRI contrast agents, won the RSNA Research Achievement Award and became one of the 10 RSNA official publicity research projects. .
In the process of imaging with MRI equipment, patients need to inject contrast agents (such as sputum) to help improve imaging quality. Helium is a heavy metal that is used in MRI testing and is generally excreted from the body after imaging is complete.
However, recent studies have found that there are still traces of residues in the human body after imaging with certain types of sputum. The impact of this residue is still unclear, but it is necessary to reduce the potential risk of patients while maximizing the quality of MRI imaging.
This study by Gong Enhao can use AI to reduce the dose of sputum used in MRI scans. They used a new deep learning algorithm in the imaging process and found that even with lower doses of sputum, MRI imaging results that were not significantly different from the full dose were obtained.
There are still many unrecognized clinical applications for lower amounts of toner use, and now more information is available through AI.
Senior overseas team
Founded in 2017, Deep Medical is the founder of Stanford Electronic Engineering, specializing in artificial intelligence imaging research, and a successful serial entrepreneur; co-founder Greg Zaharchuk is Professor Stanford and a well-known radiologist. Patent. The founding team also includes Dr. Zhang Tao from the Department of Electrical Engineering at Stanford University, Dr. Zhang Tao from the former GE Healthcare MRI, and Dr. Zhu Liren from California Institute of Technology and the University of Washington, who has many years of experience in biomedical imaging technology.
Within one year of establishment, Shenzhen Medical completed the seed round and Pre-A round of financing. The investors include the old American fund Bessemer Venture Partner, the US big data fund Data Collective, the Zhenge Fund, the well-known Silicon Valley investor Jim Breyer, BV (Baidu Ventures, Baidu Ventures and Silicon Valley New Show Fund Fusion Fund.
SubtlePET is the first AI-certified new AI technology to be developed by Deep Medical. At the same time, SubtlePET also received European CE (CONFORMITE EUROPEENNE) certification. The “CE†mark is a safety certification mark and is regarded as the only way for manufacturers to open and enter the European market.
“As the first FDA-approved AI solution for medical image enhancement processing applications, this achievement confirms the strength of our team, the commitment of our partners, and our focus on image processing and workflow. The characteristics make us very different from other AI companies that mainly do computer-assisted diagnosis or post-processing," said Gong Enhao. “This FDA certification and CE mark is an important milestone for deep penetration, but it is only the first step. We will continue to improve our technology and products and become the go to solution for hospital clinical imaging.â€
Layout globally
It is reported that SubtlePET has been clinically applied in several university hospitals and medical imaging centers in the United States and abroad. Gong Enhao revealed that the market for SubtlePET will be dominated by US hospitals and imaging centers.
Deep Medical's PET and MRI products have been collaborated with more than a dozen of the top hospitals including Stanford, UCSF, and MD Anderson for clinical testing, and will further optimize the AI ​​algorithm with more data in the future. At the same time, Deeptek Medical also works with third-party imaging centers such as RadNet to improve image quality and clinical inspection performance.
Stanford University Hospital
For hospitals in China, Europe, South America, and medical imaging companies, Shenzhen Medical is also collaborating, such as combining AI technology with imaging equipment in China and Neusoft Medical. In addition, the deep medical team also carried out clinical research cooperation with top 301 hospitals such as Tiantan.
In addition to SubtlePET, Deeptek is also developing other products that will be submitted for FDA application, including SubtleMRI and SubtleGAD for MRI (MRI), further accelerating medical image processing and reducing the amount of developer required.
Deeptek Medical is an AI medical imaging company based in Silicon Valley. It starts with "AI+ Medical Imaging" and combines deep learning and image reconstruction technology to improve the quality, efficiency and safety of medical imaging and its processes.
Since its inception, Shenzhen Medical has received two rounds of financing. The seed round comes from the US big data fund Data Collective, Zhenge Fund, BV (Baidu Ventures, Baidu Venture), Qingyuan Venture Capital, Wisemont Capital and so on.
In March of this year, Shenzhen Medical received the NVIDIA Inception “Global Medical AI Startup Company†award, which stood out from more than 3,000 startups worldwide. Deeptek Medical was also selected as the first AI+ medical project of Bessemer Venture Partner's “Deep Medical Chinese Projectâ€. At RSNA, a US heavyweight radiology conference previously reported by the Arterial Network, Deep Medical received the RSNA Research Achievement Award and became one of the 10 RSNA official publicity research projects.
In May, Shenzhen Medical completed the Pre-A round of $5 million financing, led by the US veteran fund Bessemer Venture Partner and the US Big Data Fund Data Collective, with investors including seed round investors and “World's No. 1 VC†Facebook investors. Jim Breyer and Silicon Valley rookie fund Fusion Fund.
Blood Pressure medication,Blood pressure medication,N-Acetyl-L-carnosine Online,Dacarbazine Solubility,Dacarbazine and Temozolomide,
Human APIs - Blood Pressure raw , APIs Raw powder , Antipyretic And Analgesic , Antibiotic & Antibacterial
Blood pressure medication,Blood pressure medication,N-Acetyl-L-carnosine Online,Dacarbazine Solubility,Dacarbazine and Temozolomide
Xi'an Henrikang Biotech Co.,Ltd , https://www.henruikangbio.com